Finally, although targeting DPP-4-GLP-1 signalling may improve exercise tolerance in HF patients, it has not been approved by any organizations, and we cannot draw a conclusion regarding whether type 2 diabetes mellitus patients with HF could benefit more from treatment. Here, GLP1R is linked to type 2 diabetes mellitus.